Peptides with demonstrated or researched oral bioavailability — including GLP-1 agonists, secretagogues, bioregulators, and emerging oral formulations.

Oral Peptides

Most peptides are degraded by gastric acid and proteases, making oral delivery a major pharmacological challenge. This category covers peptides that have achieved meaningful oral bioavailability through inherent stability, formulation technology, or small-molecule mimicry.

Complete Peptide Directory

Clinically Validated Oral Peptides

Peptide	Description	Oral Technology
Semaglutide Oral	Oral GLP-1 agonist FDA-approved as Rybelsus	SNAC absorption enhancer co-formulation; ~1% bioavailability
BPC-157	Gastric pentadecapeptide with demonstrated oral activity in animal models	Gastric origin provides inherent acid stability; local GI activity
BPC-157 Stable	Stabilized BPC-157 formulation optimized for oral administration	Enhanced resistance to proteolytic degradation

Oral Small-Molecule GLP-1 Agonists

Peptide	Description	Oral Technology
Orforglipron	Non-peptide oral GLP-1R agonist in Phase 3 clinical trials	Small molecule; bypasses peptide bioavailability challenges entirely
Danuglipron	Non-peptide oral GLP-1R agonist from Pfizer	Small molecule with twice-daily oral dosing

Oral Secretagogues & Metabolic Agents

Peptide	Description	Oral Technology
MK-677 (Ibutamoren)	Non-peptide oral ghrelin receptor agonist for GH secretion	Small molecule; high oral bioavailability; long-acting
5-Amino-1MQ	NNMT inhibitor for fat metabolism and NAD+ modulation	Small molecule with demonstrated oral bioavailability
NAD+	Essential coenzyme supplemented orally as NMN/NR precursors	Precursor forms (NMN, NR) are orally active
AICAR	AMPK activator and exercise mimetic	Nucleoside analog with moderate oral absorption
Glutathione	Tripeptide antioxidant with oral formulation research	Liposomal and S-acetyl formulations improve oral absorption
Octreotide	Somatostatin analog with oral formulation in development	TPGS absorption enhancer technology; octreotide oral capsules

Bioregulators with Reported Oral Activity

Khavinson bioregulators are short peptides (2-4 amino acids) reported to maintain activity when taken orally, potentially due to their small size allowing PepT1 transporter absorption.

Peptide	Size	Target Tissue
Vilon	2 amino acids (Lys-Glu)	Thymus / Immune system
Epithalon	4 amino acids	Pineal / Telomerase
Cartalax	3 amino acids	Cartilage / Skin
Cardiogen	4 amino acids	Heart
Pinealon	3 amino acids	Brain / Pineal
Cortagen	4 amino acids	Brain cortex

Common Research Themes

The Oral Barrier: Peptides face three main obstacles to oral delivery: (1) gastric acid denaturation, (2) protease degradation in the gut lumen, and (3) poor absorption across the intestinal epithelium due to size and hydrophilicity. Solutions include absorption enhancers (SNAC), enteric coatings, protease inhibitors, and permeation enhancers.

Small Molecule Mimetics: MK-677 and Orforglipron represent the strategy of developing non-peptide small molecules that activate the same receptors as natural peptides. These bypass oral bioavailability challenges entirely since they are not peptides.

Short Peptide Advantage: Di- and tripeptides can be absorbed via the PepT1 transporter in the small intestine, which may explain the reported oral activity of Khavinson bioregulators. Larger peptides generally cannot use this pathway.

BPC-157 Oral Route: BPC-157 is notable as a peptide of gastric origin that has demonstrated biological activity when administered orally in animal studies, particularly for gastrointestinal conditions. This may relate to local activity in the GI tract rather than systemic absorption.

Getting Started

If you are new to this category, we recommend starting with BPC-157 — uniquely stable in gastric acid with demonstrated oral bioavailability in preclinical models. From there, explore related peptides through the See Also sections on each page to build a comprehensive understanding of the research landscape.

Oral Peptides

On this page